Literature DB >> 20116629

[Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus].

.   

Abstract

OBJECTIVE: This review updates clinical guidelines on HIV+ and hepatitis A, B and C in coinfected adult patients.
METHODS: This consensus has been adopted by an expert panel from several scientific societies (GESIDA/SPNS/AEEH). Published data on epidemiology, natural history, prevention and treatment of viral hepatitis in HIV+ patients have been reviewed. These statements are classified according to the rating scheme of the DHHS for the strength and quality of evidence of the data. The evidence has been sub-typed as "a" and "b", depending on whether the available data were from coinfected or non-coinfected patients.
RESULTS: These guidelines focus on conditions associated with the care of the hepatic diseases, such as prevention of these hepatitis, alcohol intake, drug use, antiretroviral therapy with or without treatment of chronic hepatitis. Follow-up is individualised, based on virological data and non-invasive assessment of liver fibrosis. Several nucleoside/nucleotide analogues have activity against HBV and HIV, so the majority of the patients will receive combined therapy. A significant proportion of patients can resolve HCV infection. It is important to select the patient appropriately and a good knowledge of these therapies is required. With advanced liver disease, it may be necessary to adapt HAART and consider liver transplantation.
CONCLUSIONS: We have effective drugs and diagnostic procedures in order to evaluate all coinfected patients and consider a high proportion suitable for therapy against hepatitis viruses. These patients should have the same therapeutic options as the general population. Copyright 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20116629     DOI: 10.1016/j.eimc.2009.12.001

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  7 in total

1.  Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.

Authors:  M Guzmán-Fulgencio; J Berenguer; D Pineda-Tenor; M A Jiménez-Sousa; M García-Álvarez; T Aldámiz-Echevarria; A Carrero; C Diez; F Tejerina; S Vázquez; V Briz; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-19       Impact factor: 3.267

2.  rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.

Authors:  Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Ana Carrero; Mónica García-Álvarez; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Cristina Diez; María Guzmán-Fulgencio; Amanda Fernández-Rodríguez; Salvador Resino
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-29       Impact factor: 2.205

3.  Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.

Authors:  Fernando Salvador; Israel Molina; Elena Sulleiro; Joaquín Burgos; Adrián Curran; Eva Van den Eynde; Sara Villar del Saz; Jordi Navarro; Manuel Crespo; Inma Ocaña; Esteve Ribera; Vicenç Falcó; Albert Pahissa
Journal:  Am J Trop Med Hyg       Date:  2013-03-18       Impact factor: 2.345

4.  Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.

Authors:  María Guzmán-Fulgencio; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Ana Carrero; Mónica García-Álvarez; Francisco Tejerina; Cristina Diez; Sonia Vazquez-Morón; Salvador Resino
Journal:  J Transl Med       Date:  2015-06-30       Impact factor: 5.531

5.  Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.

Authors:  Luz M Medrano; Norma Rallón; Juan Berenguer; María A Jiménez-Sousa; Vicente Soriano; Teresa Aldámiz-Echevarria; Amanda Fernández-Rodríguez; Marcial García; Francisco Tejerina; Isidoro Martínez; José M Benito; Salvador Resino
Journal:  J Transl Med       Date:  2016-09-02       Impact factor: 5.531

6.  Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.

Authors:  Mónica García-Álvarez; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Francisco Tejerina; Cristina Diez; Sonia Vázquez-Morón; Salvador Resino
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

7.  ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients.

Authors:  Luz M Medrano; Juan Berenguer; María A Jiménez-Sousa; Teresa Aldámiz-Echevarria; Francisco Tejerina; Cristina Diez; Lorena Vigón; Amanda Fernández-Rodríguez; Salvador Resino
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.